outcome of Meeting
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 consolidated revenue of Rs. 3,82,167 lakhs, up 1.9% from Rs. 3,74,921 lakhs in FY2025. Profit after tax grew 11.7% to Rs. 103,598 lakhs from Rs. 92,758 lakhs. Standalone PAT increased 10.1% to Rs. 101,182 lakhs. The Board recommended a final dividend of Rs. 57 per share (face value Rs. 10), up from Rs. 42 per share in FY2025. Cash and cash equivalents stood at Rs. 1,10,205 lakhs as of March 31, 2026. Statutory auditors Deloitte Haskins & Sells issued unmodified opinions on both standalone and consolidated financial statements. Exceptional items included gains from sale of surplus properties (Rs. 2,062 lakhs consolidated). Record date for dividend is May 29, 2026.
The company delivered double-digit PAT growth driven by improved margins and cost management despite modest revenue growth. The 35.6% increase in dividend per share signals strong confidence in cash generation. Clean audit opinions with no going concern issues support financial stability. The stock appears fundamentally solid with improved profitability.